Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | NPR3 | P17342 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753754 | 0.94 | MEN1 (0.44) | L3MBTL1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL1753516 | 0.94 | MEN1 (0.44) | L3MBTL1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL1753783 | 0.93 | RXFP1 (0.36) | RXFP1RAB9AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL1753510 | 0.92 | MEN1 (0.45) | RXFP1L3MBTL1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1753753 | 0.92 | MEN1 (0.45) | RXFP1L3MBTL1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL1753584 | 0.80 | MEN1 (0.46) | L3MBTL1SMN1; SMN2NLRP3MEN1KMT2A | |
| SCHEMBL1753759 | 0.79 | MEN1 (0.46) | L3MBTL1SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL1753582 | 0.77 | MEN1 (0.54) | RXFP1RAB9AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL19901428 | 0.77 | MEN1 (0.54) | RXFP1RAB9AL3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL13411037 | 0.74 | ALDH1A1 (0.44) | RAB9AHPGDSMN1; SMN2NPC1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | RXFP1 1025/4885RAB9A 2555/4885L3MBTL1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.